CLAIMS

1. An antigen-binding molecule comprising:
(1) a cancer-specific antigen-binding domain; and
(2) a tumor necrosis factor (TNF) superfamily-binding domain or a tumor necrosis factor (TNF) receptor superfamily-binding domain.

2. The antigen-binding molecule of claim 1, further comprising an FcRn-binding domain, inparticular wherein the FcRn-binding domain is an antibody Fc region having decreased Fcγ receptor-binding activity.

3. The antigen-binding molecule of claim 1 or 2, wherein the TNF superfamily-binding domain or the TNF receptor superfamily-binding domain is a CD137-binding domain.

4. The antigen-binding molecule of any one of claims 1 to 3, which is a bispecific antibody.

5. A pharmaceutical composition comprising as an active ingredient the antigen-binding molecule of any one of claims 1 to 4.

6. The pharmaceutical composition of claim 5, which is a cytotoxicity-inducing composition.

7. The pharmaceutical composition of claim 5, which is a composition for use in the treatment of cancer.

8. A pharmaceutical composition comprising a combination of a first antigen-binding molecule of any one of claims 1 to 4, and a second antigen-binding molecule that comprises:
(1) a cancer-specific antigen-binding domain; and
(2) a T cell receptor complex-binding domain.

9. Use of a combination of:

a first antigen-binding molecule comprising:

(1) a cancer-specific antigen-binding domain; and

(2) a tumor necrosis factor (TNF) superfamily-binding domain or a tumor necrosis factor (TNF) receptor superfamily-binding domain, and

a second antigen-binding molecule comprising:

(1) a cancer-specific antigen-binding domain; and

(2) a T cell receptor complex-binding domain,

in the manufacture of a medicament for the treatment of cancer.

10. The composition of claim 8 or the use of claim 9, wherein the second antigen-binding molecule is an antigen-binding molecule that further comprises an FcRn-binding domain, inparticular wherein the FcRn-binding domain is an antibody Fc region having decreased Fcγ receptor-binding activity.

11. The composition or use of any one of preceding claims, wherein the TNF superfamily-binding domain or the TNF receptor superfamily-binding domain of the first antigen-binding molecule is a CD137-binding domain.

12. The composition or use of any one of the preceding claims, wherein the T cell receptor complex-binding domain is a T cell receptor-binding domain.

13. The composition or use of any one of the preceding claims, wherein the T cell receptor complex-binding domain is a CD3-binding domain.

14. The composition or use of any one of the preceding claims, wherein the second antigen-binding molecule is a bispecific antibody.

15. The composition or use of any one of the preceding claims, wherein the first antigen-binding molecule and the second antigen-binding molecule are mixed, are to be used concomitantly, or are to be administered either simultaneously or separately.

16. The composition or use of any one of claims 8 to 15, wherein the composition or medicament is cytotoxicity-inducing composition.

17. The composition of any one of claims 8 or 10 to 15, which is a composition for use in the treatment of cancer.

18. A pharmaceutical composition comprising as an active ingredient a first antigen-binding molecule that comprises:

(1) a cancer-specific antigen-binding domain; and

(2) a tumor necrosis factor (TNF) superfamily-binding domain or a tumor necrosis factor (TNF) receptor superfamily-binding domain,

for concomitant use with a second antigen-binding molecule that comprises:

(1) a cancer-specific antigen-binding domain; and

(2) a T cell receptor complex-binding domain.

19. Use of a first antigen-binding molecule comprising:

(1) a cancer-specific antigen-binding domain; and

(2) a tumor necrosis factor (TNF) superfamily-binding domain or a tumor necrosis factor (TNF) receptor superfamily-binding domain, for concomitant use with a second antigen-binding molecule that comprises:

(1) a cancer-specific antigen-binding domain; and

(2) a T cell receptor complex-binding domain

in the manufacture of a medicament for the treatment of cancer.

20. The composition of claim 18 or the use of claim 19, where in the composition or medicament is cytotoxicity-inducing.

21. The composition of claim 18, which is a composition for use in the treatment of cancer.

22. The composition or use of any one of claims 18 to 21, wherein the first antigen-binding molecule and/or the second antigen-binding molecule is an antigen-binding molecule that further comprises an FcRn-binding domain, inparticular wherein the FcRn-binding domain is an antibody Fc region having decreased Fcγ receptor-binding activity.

23. The composition or use of any one of claims 18 to 22, wherein the TNF superfamily-binding domain or the TNF receptor superfamily-binding domain is a CD137-binding domain or a CD40-binding domain.

24. The composition or use of any one of claims 18 to 23, wherein the T cell receptor complex-binding domain is a T cell receptor-binding domain.

25. The composition or use of any one of claims 18 to 23, wherein the T cell receptor complex-binding domain is a CD3-binding domain.

26. The composition or use of any one of claims 18 to 25, wherein the first antigen-binding molecule and/or the second antigen-binding molecule is a bispecific antibody.

27. The pharmaceutical composition of any one of claims 18 to 26, which is to be administered either simultaneously with or separately from the second antigen-binding molecule.

28. A pharmaceutical composition comprising as an active ingredient a second antigen-binding molecule that comprises:

(1) a cancer-specific antigen-binding domain; and

(2) a T cell receptor complex-binding domain,

for concomitant use with a first antigen-binding molecule that comprises:

(1) a cancer-specific antigen-binding domain; and

(2) a tumor necrosis factor (TNF) superfamily-binding domain or a tumor necrosis factor (TNF) receptor superfamily-binding domain.

29. Use of a second antigen-binding molecule comprising:

(1) a cancer-specific antigen-binding domain; and

(2) a T cell receptor complex-binding domain,

for concomitant use with a first antigen-binding molecule that comprises:

(1) a cancer-specific antigen-binding domain; and

(2) a tumor necrosis factor (TNF) superfamily-binding domain or a tumor necrosis factor (TNF) receptor superfamily-binding domain in the manufacture of a medicament for the treatment of cancer.

30. The composition of claim 28 or the use of claim 29, wherein the composition or medicament is cytotoxicity-inducing composition.

31. The composition of claim 28, which is a composition for use in the treatment of cancer.

32. The composition or use of any one of claims 28 to 31, wherein the first antigen-binding molecule and/or the second antigen-binding molecule is an antigen-binding molecule that further comprises an FcRn-binding domain, inparticular wherein the FcRn-binding domain is an antibody Fc region having decreased Fcγ receptor-binding activity.

33. The composition or use of any one of claims 28 to 32, wherein the T cell receptor complex-binding domain is a T cell receptor-binding domain.

34. The composition or use of any one of claims 28 to 32, wherein the T cell receptor complex-binding domain is a CD3-binding domain.

35. The composition or use of any one of claims 28 to 34, wherein the TNF superfamily-binding domain or the TNF receptor superfamily-binding domain is a CD137-binding domain or a CD40-binding domain.

36. The composition or use of any one of claims 28 to 35, wherein the first antigen-binding molecule and/or the second antigen-binding molecule is a bispecific antibody.

37. The composition or use of any one of claims 28 to 36, which is to be administered either simultaneously with or separately from the first antigen-binding molecule.